Topics:

Diabetes

Diabetes

GI side effects can lead patients to stop GLP-1 agonist therapy. Identifying risk factors for these adverse events could help improve patient selection.

Incretin-based therapies have shown beneficial effects on the cardiovascular system, providing impetus for this recent study.

Try this mid-week Q&A on 2 essential properties of the sodium glucose cotransporter 2 (SGLT2) inhibitors.

What do you get when you combine an SGLT2 inhibitor and a GLP-1 receptor agonist into therapy for 1 diabetes patient?

Our endo blogger has her theories about why doing what you thought you loved just seems to sap your soul.

There are several reasonable options for intensifying this patient's blood pressure treatment. Which one is optimal, though, given his labs and concomitant meds?

Some key classes of antidiabetes agents could play a dual physiologic role. Find out which ones hold most promise in this at-a-glance summary.

Pages

Subscribe to Diabetes on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.